Evidence map›Paper›PMID 42711715›Full record

ArticleJournal of nanobiotechnology2026

A portable nanobiosensor with machine learning: enabling multi-cytokines point-of-care testing and early identification of sepsis immunoparalysis.

Rongjun Yu, Jiangling Wu, Anyi Chen, Jianjiang Xue, Sihan Guo, Siling Chen, Shanshan Dong, Li Li, Xiao Gui, LiLin Wang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rongjun Yu *Department of Clinical Laboratory and Medical Sciences Research Center, University-Town Hospital of Chongqing Medical University, Chongqing, 401331, P. R. China.
Jiangling Wu *Department of Clinical Laboratory and Medical Sciences Research Center, University-Town Hospital of Chongqing Medical University, Chongqing, 401331, P. R. China.
Anyi Chen *School of Public Health and Management, Chongqing Medical University, Chongqing, 400016, P. R. China.
Jianjiang XueDepartment of Clinical Laboratory and Medical Sciences Research Center, University-Town Hospital of Chongqing Medical University, Chongqing, 401331, P. R. China.
Sihan GuoDepartment of Clinical Laboratory and Medical Sciences Research Center, University-Town Hospital of Chongqing Medical University, Chongqing, 401331, P. R. China.
Siling ChenDepartment of Clinical Laboratory and Medical Sciences Research Center, University-Town Hospital of Chongqing Medical University, Chongqing, 401331, P. R. China.
Shanshan DongDepartment of Clinical Laboratory and Medical Sciences Research Center, University-Town Hospital of Chongqing Medical University, Chongqing, 401331, P. R. China.
Li LiDepartment of Clinical Laboratory and Medical Sciences Research Center, University-Town Hospital of Chongqing Medical University, Chongqing, 401331, P. R. China.
Xiao GuiDepartment of Clinical Laboratory and Medical Sciences Research Center, University-Town Hospital of Chongqing Medical University, Chongqing, 401331, P. R. China.
LiLin WangDepartment of Clinical Laboratory and Medical Sciences Research Center, University-Town Hospital of Chongqing Medical University, Chongqing, 401331, P. R. China.
Gang TianDepartment of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Sichuan Province Engineering Technology Research Center of Molecular Diagnosis of Clinical Diseases, Molecular Diagnosis of Clinical Diseases Key Laboratory of Luzhou, Sichuan, 646000, P. R. China.
Gang LiuDepartment of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China. lg@cqmu.edu.cn.
Jingfu QiuSchool of Public Health and Management, Chongqing Medical University, Chongqing, 400016, P. R. China. jfqiu@126.com.
Weixian ChenDepartment of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China. chenweixian@cqmu.edu.cn.

Funding

Chongqing Municipal Science and Health Joint Medical Research Youth Project 2024QNXM039National Natural Science Foundation of China 22204014National Natural Science Foundation Pre-research Program JYDX2026NSFC03
6 · The paper itself

Abstract

Sepsis immunoparalysis (SIs) is a major factor contributing to organ dysfunction. However, emergency departments (EDs) and intensive care units (ICUs) currently lack a rapid workflow for early identification of SIs. Herein, an innovative strategy for early SIs identification is proposed. We construct a portable nanobiosensor based on the Nanozyme-Linked Immunosorbent Assay (NLISA) for ultrasensitive and specific Multi-Cytokines quantification, benefiting from its advantages of parallel, independent, rapid, and portable detection. Machine learning is applied to process Multi-Cytokines concentration data measured under varied conditions and build an early identification model for rapid and effective sepsis immunoparalysis diagnosis. This method achieves point-of-care testing (POCT) with small plasma sample volumes (30 µL), with a detection limit as low as 3.8 fg mL

Indexed as

Biosensing TechniquesCytokinesMachine LearningPoint-of-Care TestingSepsisEnzyme-Linked Immunosorbent AssayHumansLimit of DetectionRapid Diagnostic TestsCytokinesMachine learningMulti-cytokines point-of-care testingNanozyme-linked immunosorbent assayPortable nanobiosensorSepsis immunoparalysis

Identifiers

PMID42711715
PMCPMC13551774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.